Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer

Por K. K. Laktionov, E. V. Reutova
Publicado em 2019-06-01

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience

Por K. K. Laktionov, E. V. Reutova, S. Yu. Kruteleva, E. Yu. Antonova
Publicado em 2021-12-01

Rational approach to the treatment of EGFR-positive lung cancer

Por E. V. Reutova, K. K. Laktionov, D. I. Yudin, M. S. Ardzinba
Publicado em 2019-12-01

TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT

Por K. K. LAKTIONOV, E. V. REUTOVA, M. S. ARDZINBA, N. A. MESCHERYAKOVA
Publicado em 2017-06-01

Experience of using сrizotinib in patients with ALKpositive non-small cell lung cancer

Por E. V. Reutova, L. V. Laktionova, D. T. Marinov, D. A. Peregudov, T. N. Borisova
Publicado em 2020-07-01

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Por K. A. Sarantseva, K. K. Laktionov, E. V. Reutova, D. I. Yudin, V. V. Breder
Publicado em 2020-12-01

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment

Por A. E. Kuzminov, T. N. Borisova, V. V. Breder, E. V. Reutova, T. D. Barbolina, K. K. Laktionov
Publicado em 2020-07-01

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Por K. K. Laktionov, K. A. Sarantseva, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov
Publicado em 2019-12-01

A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Por K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, K. P. Laktionov, V. V. Breder, E. V. Reutova
Publicado em 2018-07-01

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Por D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, M. S. Ardzinba, E. V. Reutova, O. I. Borisova
Publicado em 2021-08-01

Pseudoprogression in patients on immunotherapy

Por D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, E. V. Reutova, O. I. Borisova, M. S. Ardzinba
Publicado em 2019-06-01

Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation

Por L. A. Nelyubina, E. V. Reutova, K. K. Laktionov, D. I. Yudin, D. T. Marinov, E. N. Kozak, V. V. Mochalnikova
Publicado em 2018-11-01

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Por K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba
Publicado em 2019-06-01

THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

Por К. К. LAKTIONOV, М. V. PEREGUDOVA, V. V. BREDER, E. V. REUTOVA, D. A. PEREGUDOV, M. S. ARDZINBA, P. A. CHERNENKO, D. T. MARINOV
Publicado em 2016-12-01

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients

Por K. K. Laktionov, V. V. Breder, D. I. Yudin, K. A. Sarantseva, L. V. Laktionova, M. S. Ardzinba, E. V. Reutova, A. V. Egorova
Publicado em 2019-12-01

Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer

Por N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, E. V. Reutova, Merab S. Ardzinba, V. L. Utkina, T. N. Borisova, A. A. Fedorova, Milada S. Ardzinba
Publicado em 2020-12-01

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

Por D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, O. I. Borisova, V. V. Breder, E. V. Reutova, M. F. Beloyartseva, S. Yu. Kruteleva, I. A. Dzhanyan
Publicado em 2020-07-01

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

Por K K Laktionov, E V Reutova, L A Nelyubina, M Yu Pitkevich, M A Okruzhnova, M S Ardzinba, D I Yudin, I A Demidova, A R Zaretsky
Publicado em 2018-06-01